The South & Central America acute pancreatitis market was valued at US$ 209.04 million in 2022 and is expected to reach US$ 333.67 million by 2030; it is estimated to grow at a CAGR of 6.0% from 2022 to 2030.
Further, several ongoing international efforts are being made to define the epidemiology and pathophysiology of acute pancreatitis. The National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH), formed a collaborative network of 10 clinical centers and 1 data coordination center in 2020 to address several knowledge gaps regarding acute pancreatitis. The consortium is referred to as Type 1 Diabetes after Acute Pancreatitis Consortium (T1DAPC). Thus, R&D activities and awareness programs on acute pancreatitis for the development of effective therapies (through direct and indirect means) are expected to be highly fruitful for companies in the South & Central America acute pancreatitis market.
Based on offerings, the South & Central America acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest market share in 2022.
Based on causes, the South & Central America acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held the largest market share in 2022.
Based on end user, the South & Central America acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held the largest market share in 2022.
Based on country, the South & Central America acute pancreatitis market is segmented into Brazil, Argentina, and the Rest of South & Central America. The Rest of South & Central America dominated the South & Central America acute pancreatitis market share in 2022.
Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare are some of the leading companies operating in the South & Central America acute pancreatitis market.
Reasons to Buy
Upsurge in Number of R&D Activities and Awareness Programs on Acute Pancreatitis Fuels the South & Central America Acute Pancreatitis Market
Extensive research studies are being conducted globally to investigate the etiology, progress, and treatment of acute pancreatitis. The National Pancreas Foundation (NPF) provides multiple research grants worth ~US$ 50,000 per project. To date, the NPF has provided more than US$ 5 million for 133 ground-breaking research projects. A grant is awarded for a period of a year to diagnose and/or treat pancreatitis, pancreatic cancer, or pediatric pancreatitis.Further, several ongoing international efforts are being made to define the epidemiology and pathophysiology of acute pancreatitis. The National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH), formed a collaborative network of 10 clinical centers and 1 data coordination center in 2020 to address several knowledge gaps regarding acute pancreatitis. The consortium is referred to as Type 1 Diabetes after Acute Pancreatitis Consortium (T1DAPC). Thus, R&D activities and awareness programs on acute pancreatitis for the development of effective therapies (through direct and indirect means) are expected to be highly fruitful for companies in the South & Central America acute pancreatitis market.
South & Central America Acute Pancreatitis Market Overview
The South & Central America acute pancreatitis market is segmented into Brazil, Argentina, and the Rest of South & Central America. Increasing in geriatric population in the region and increase in cases of acute pancreatitis is fueling the growth of the South & Central America acute pancreatitis market in the region. Acute pancreatitis is a life-threatening disease, especially in the geriatric population due to co-morbidities and compromised body systems. As per Brazil's Ministry of Health, by 2030, Brazil is anticipated to rank fifth in terms of geriatric population worldwide. The WHO estimated that the elderly population will have increased by more than 300% and the overall population will grow by 30% by 2050 in the country. According to Pan American Health Organization (PAHO), in 2022, Brazil had more than 30 million people aged above 60, which represents 30% of the total population. The number of people aged above 60 is expected to reach ~50 million, which is expected to represent 24% of the total population of Brazil by 2050. Apart from aging, alcohol consumption can also cause acute pancreatitis. According to an article published in Nature, 85.2% of the total alcohol drinkers were heavy drinkers in Brazil. Thus, the increase in alcohol consumption in Brazil is also fueling the growth of the South & Central America acute pancreatitis market.South & Central America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
South & Central America Acute Pancreatitis Market Segmentation
The South & Central America acute pancreatitis market is segmented offerings, causes, end user, and country.Based on offerings, the South & Central America acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest market share in 2022.
Based on causes, the South & Central America acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held the largest market share in 2022.
Based on end user, the South & Central America acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held the largest market share in 2022.
Based on country, the South & Central America acute pancreatitis market is segmented into Brazil, Argentina, and the Rest of South & Central America. The Rest of South & Central America dominated the South & Central America acute pancreatitis market share in 2022.
Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare are some of the leading companies operating in the South & Central America acute pancreatitis market.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America acute pancreatitis market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in South & Central America acute pancreatitis market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. South & Central America Acute Pancreatitis Market Landscape
5. South & Central America Acute Pancreatitis Market - Key Industry Dynamics
6. Acute Pancreatitis Market - South & Central America Market Analysis
7. South & Central America Acute Pancreatitis Market - Revenue and Forecast to 2030 - by Offerings
8. South & Central America Acute Pancreatitis Market - Revenue and Forecast to 2030 - by Causes
9. South & Central America Acute Pancreatitis Market - Revenue and Forecast to 2030 - by End User
10. South & Central America Acute Pancreatitis Market - Country Analysis
11. South & Central America Acute Pancreatitis Market-Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned
- Abbott Laboratories
- Baxter International Inc
- Boston Scientific Corp
- Fresenius Kabi AG
- GE HealthCare Technologies Inc
- Koninklijke Philips NV
- Medtronic Plc
- Samsung Healthcare